Skip to main content

Advertisement

Table 3 Comparison between plasma lipid changes induced by monotherapy with BBR/P/RR (n. 14 subjects) or EZE (n. 12 subjects) and combined therapy with BBR/P/RR plus EZE in HCH patients

From: Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment

Lipid parameter Baseline Monotherapy % changes Combined therapy % changes P
TC (mmol/L) 7.74 ± 0.40 6.34 ± 0.40* −18.0 ± 3.5 5.59 ± 0.40 −27.7 ± 3.8 < 0.001
LDL-C (mmol/L) 5.47 ± 0.51 4.19 ± 0.48* −23.5 ± 3.5 3.44 ± 0.44 −37.1 ± 4.5 < 0.001
HDL-C (mmol/L) 1.58 ± 0.40 1.59 ± 0.42 +0.17 ± 8.2 1.60 ± 0.42 +1.10 ± 5.7 NS
non-HDL-C (mmol/L) 6.15 ± 0.59 4.75 ± 0.57* −22.8 ± 3.8 3.98 ± 0.49 −35.3 ± 4.2 < 0.001
TG (mmol/L) 1.48 (1.08-1.89) 1.12 (0.95-1.47)* −18.6 ± 15.5 1.09 (0.94-1.35) −23.1 ± 12.9 < 0.005
  1. Values are means ± SD or medians (interquartile ranges). *P <0.001 vs baseline values and P <0.001 vs monotherapy; P: significance of the differences between percent changes induced by monotherapy and by combined therapy (Student’s t test for paired data or Wilcoxon test, respectively). NS: not significant.